Update from the annual meeting of the American Society of Hematology (ASH) suggested that initial data for Fate Therapeutics Inc’s (NASDAQ: FATE) FT500 and FT516 therapies were well received by both clinicians and investors, according to Wells Fargo.
Wells Fargo’s Jim Birchenough upgraded Fate Therapeutics from Equal-Weight to Overweight, while raising the price target from $16 to $24.
Fate Therapeutics reviewed progress with its induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapeutics pipeline at the ASH meeting, which suggests upside potential in 2020, Birchenough said in the note.
Phase 1 data of FT500 indicates that repeat dosing is safe and “incites neither a host anti-FT500 T-cell nor a B-cell response,” the analyst mentioned.
He added that “very early clinical data for FT516 as a monotherapy in acute myeloid leukemia or with RITUXAN in non-Hodgkin lymphoma are encouraging suggesting that iPSC-NK are functional.”
Moreover, FT596 is scheduled to begin clinical studies in early 2020, while FT819 can be manufactured at good manufacturing practice (GMP) scale and shows improved pre-clinical activity against a conventional CAR-T.
Birchenough highlighted that Fate Therapeutics had dosed all the iPSC NK products in the outpatient setting without incident.
Shares of Fate Therapeutics had spiked almost 41% to $19.27 at the time of publishing on Monday.
Latest Ratings for FATE
|Dec 2019||Upgrades||Market Perform||Outperform|
|Nov 2019||Initiates Coverage On||Buy|
View More Analyst Ratings for FATE
View the Latest Analyst Ratings
See more from Benzinga
- Wells Fargo Upgrades Ingersoll-Rand On Higher ClimateCo Potential
- Cloudera Delivers Beat And Raise, But Growth Remains Lower Than Industry Rates
- CrowdStrike Delivers Another Quarterly Beat With Improvement In Key Parameters
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.